Medical Editor: John P. Cunha, DO, FACOEP
What Is Impoyz?
Impoyz (clobetasol propionate) Cream is a corticosteroid indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age and older. Impoyz is available in generic form.
What Are Side Effects of Impoyz?
Common side effects of Impoyz include application site discoloration.
Dosage for Impoyz
Apply a thin layer dose of Impoyz Cream to the affected skin areas twice daily and rub in gently and completely. Wash hands after each application. Use Impoyz Cream for up to 2 consecutive weeks of treatment.
What Drugs, Substances, or Supplements Interact with Impoyz?
Impoyz may interact with other drugs. Tell your doctor all medications and supplements you use, especially other corticosteroids you use.
Impoyz During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Impoyz; it is unknown how it would affect a fetus. During pregnancy, use Impoyz Cream on the smallest area of skin and for the shortest time needed. It is unknown if Impoyz passes into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Impoyz (clobetasol propionate) Cream, 0.025%, for Topical Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
SLIDESHOW
Types of Psoriasis: Medical Pictures and Treatments See Slideshow
SIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice.
IMPOYZ Cream was evaluated in two randomized, multicenter, prospective, vehicle-controlled clinical trials in subjects with moderate to severe plaque psoriasis. Subjects applied IMPOYZ Cream or vehicle cream twice daily for 14 days. A total of 354 subjects applied IMPOYZ Cream and 178 subjects applied vehicle.
The adverse reaction that occurred in at least 1% of subjects treated with IMPOYZ Cream and at a higher incidence than in subjects treated with vehicle cream was application site discoloration (2% versus 1%).
Less common local adverse events occurring in < 1% of subjects treated with IMPOYZ Cream were application site atrophy, telangiectasia and rash.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of clobetasol propionate: striae, irritation, dryness, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, hypertrichosis, and miliaria. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read the entire FDA prescribing information for Impoyz (Clobetasol Propionate Cream)
